American pharmaceutical giant- Pfizer has reportedly announced that the U.S. Food and Drug Administration (FDA) has sanctioned the use of a supplemental NDA (new drug application) for Lorbrena or lorlatinib, that expands the indication of the drug to

Israel-based SciSparc Ltd.- a clinical-stage pharmaceutical firm that develops cannabinoid-based treatment solutions, has reportedly announced that it has entered into an agreement with the Israeli Medical Center for Alzheimer’s to facilitate